Epidemiology and aetiological factors

The Spina Bifida: Management and Outcome

Volumn , Issue , 2008, Pages 59-65

  Josan, Vivek ^a   Morokoff, Andrew ^a   Maixner, Wirginia J ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73349130213     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-0651-5_4     Document Type: Chapter

References (48)

1. Fidas A, MacDonald HL, Elton RA et al (1987) Prevalence and patterns of spina bifida occulta in 2707 normal adults. Clin Radiol 38:537-542
2. Boone D, Parsons D, Lachmann SM et al (1985) Spina bifida occulta: lesion or anomaly? Clin Radiol 36:159-161
3. Nikkila A, Rydhstrom H, Kallen B (2006) The incidence of spina bifida in Sweden 1973-2003: the effect of prenatal diagnosis. Eur J Pub Health 16:660-662
4. Bower C, Raymond M, Lumley J et al (1993) Trends in neural tube defects 1980-1989. Med J Aus 158:152-154
5. Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986. EUROCAT Working Group (1991) J Epidemiol Comm Health 45:52-58
6. Prevalence of neural tube defects in 16 regions of Europe, 1980-1983. The EUROCAT Working Group (1987) Int J Epidemiol 16:246-251
7. Frey L, Hauser WA (2003) Epidemiology of neural tube defects. Epilepsia 44:4-13
8. Canfield MA, Annegers JF, Brender JD et al (1996) Hispanic origin and neural tube defects in Houston/Harris County, Texas. II. Risk factors. Am J Epidemiol 143:12-24
9. Elwood JH (1973) Epidemics of anencephalus and spina bifida in Ireland since 1900. Int J Epidemiol 2:171-175
10. Janerich DT (1973) Epidemic waves in the prevalence of anencephaly and spina bifida in New York State. Teratology 8:253-256
11. Rosano A, Smithells D, Cacciani L et al (1999) Time trends in neural tube defects prevalence in relation to preventive strategies: an international study. J Epidemiol Comm Health 53:630-635
12. Papp C, Adam Z, Toth-Pal E et al (1997) Risk of recurrence of craniospinal anomalies. J Matern Fetal Med 6:53-57
13. Elwood JM, Little J, Elwood JH (1992) Epidemiology and control of neural tube defects. Oxford University Press
14. Schwahn B, Rozen R (2001) Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 1:189-201
15. Van Der Put NM, Steegers-Theunissen RP, Frosst P et al (1995) Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070-1071
16. Van Der Linden IJ, Afman LA, Heil SG et al (2006) Genetic variation in genes of folate metabolism and neural-tube defect risk. Proc Nutr Soc 65:204-215
17. Chatkupt S, Chatkupt S, Johnson WG (1993) Waardenburg syndrome and myelomeningocele in a family. J Med Gen 30:83-84
18. Hol FA, Geurds MP, Chatkupt S et al (1996) PAX genes and human neural tube defects: an amino acid substitution in PAX1 in a patient with spina bifida. J Med Gen 33:655-660
19. Melvin EC, George TM, Worley G et al (2000) Genetic studies in neural tube defects. NTD Collaborative Group. Pediatr Neurosurg 32:1-9
20. Van Straaten HW, Copp AJ (2001) Curly tail: a 50-year history of the mouse spina bifida model. Anat Embryol 203:225-237
21. Harris MJ, Juriloff DM (2007) Mouse mutants with neural tube closure defects and their role in understanding human neural tube defects. Birth Defects Res 79:187-210
22. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study (1991) MRC Vitamin Study Research Group. Lancet 338:131-137
23. Roe DA (1978) Lucy Wills (1888-1964). A biographical sketch. J Nutr 108:1379-1383
24. Thiersch JB (1952) Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino PGA) administered by the oral route. Am J Obstet Gynecol 63:1298-1304
25. Laurence KM, James N, Miller MH et al (1981) Doubleblind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed) 282:1509-1511
26. Smithells RW, Sheppard S, Schorah CJ (1976) Vitamin deficiencies and neural tube defects. Arch Dis Child 51:944-950
27. Smithells RW, Nevin NC, Seller MJ et al (1983) Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1:1027-1031
28. Pitkin RM (2007) Folate and neural tube defects. Am J Clin Nutr 85:285S-288S
29. Czeizel AE, Dudas I, Fritz G et al (1992) The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet 251:181-185
30. Shaw GM, Velie EM, Schaffer D (1996) Risk of neural tube defect-affected pregnancies among obese women. JAMA 275:1093-1096
31. Chambers CD, Johnson KA, Dick LM et al (1998) Maternal fever and birth outcome: a prospective study. Teratology 58:251-257
32. McNulty H, Cuskelly GJ, Ward M (2000) Response of red blood cell folate to intervention: implications for folate recommendations for the prevention of neural tube defects. Am J Clin Nutr 71:1308S-1311S
33. Botto LD, Lisi A, Bower C et al (2006) Trends of selected malformations in relation to folic acid recommendations and fortification: an international assessment. Birth Defects Res 76:693-705
34. Bower C, Stanley FJ (2004) Case for mandatory fortification of food with folate in Australia, for the prevention of neural tube defects. Birth Defects Res 70:842-843
35. Lawrence M (2006) Evaluation of the implementation of the folate-neural tube defect health claim and its impact on the availability of folate-fortified food in Australia. Aust N Z J Public Health 30:363-368
36. Dietrich M, Brown CJ, Block G et al (2005) The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr 24:266-274
37. De Wals P, Tairou F, Van Allen MI et al (2007) Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 357:135-142
38. Spina bifida and anencephaly before and after folic acid mandate-United States, 1995-1996 and 1999-2000 (2004) MMWR 53:362-365
39. Ray JG, Meier C, Vermeulen MJ et al (2002) Association of neural tube defects and folic acid food fortification in Canada. Lancet 360:2047-2048
40. Hertrampf E, Cortes F (2004) Folic acid fortification of wheat flour: Chile. Nutr Rev 62:S44-48; discussion S49
41. Bower C, De Klerk N, Hickling S et al (2006) Assessment of the potential effect of incremental increases in folic acid intake on neural tube defects in Australia and New Zealand. Aust N Z J Public Health 30:369-374
42. Ward M, McNulty H, Pentieva K et al (2000) Fluctuations in dietary methionine intake do not alter plasma homocysteine concentration in healthy men. J Nutr 130:2653-2657
43. Taylor MJ, Carney SM, Goodwin GM et al (2004) Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol (Oxford, England) 18:251-256
44. Durga J, Van Boxtel MP, Schouten EG et al (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369:208-216
45. FSANZ: Food Standards Australia and New Zealand Report 23 May 2007. http://www.foodstandards.gov. au/-srcfiles/P295%20Folate%20Fortification%20FFR %20+%20Attach%201%20FINAL.pdf.
46. Mills JL, Von Kohorn I, Conley MR et al (2003) Low vitamin B-12 concentrations in patients without anemia: the effect of folic acid fortification of grain. Am J Clin Nutr 77:1474-1477
47. Flood VM, Smith WT, Webb KL et al (2006) Prevalence of low serum folate and vitamin B12 in an older Australian population. Aust N Z J Public Health 30:38-41
48. Van Guelpen B, Hultdin J, Johansson I et al (2006) Low folate levels may protect against colorectal cancer. Gut 55:1461-1466